Lupin Launches Partnership Program Following FDA Approval of PrecisionSphere Injectable Platform

Lupin announces strategic partnership program to expand reach of its long-acting injectable platform

NAPLES, Fla. – Global pharma major Lupin has launched a strategic partnership program aimed at expanding the reach of PrecisionSphere– the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi. PrecisionSphere demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent United States Food and Drug Administration's (U.S. FDA) approval for the first product developed with this platform…

Lupin Launches Partnership Program Following FDA Approval of PrecisionSphere Injectable Platform

Lupin has announced the launch of a strategic partnersh […] The post Lupin Launches Partnership Program Following FDA Approval of PrecisionSphere Injectable Platform first appeared on GeneOnline News. The post Lupin Launches Partnership Program Following FDA Approval of PrecisionSphere Injectable Platform appeared first on GeneOnline News.

Lupin launches strategic partnership program to expand reach of its long-acting injectable platform - Express Pharma

Global pharma company Lupin Limited announced the launch of a strategic partnership programme to expand the reach of its PrecisionSphere platform, a long-acting injectable (LAI) technology developed by its subsidiary, Nanomi B.V. The platform has received approval from the United States Food and Drug Administration (U.S. FDA) for the first product developed using it and is ready for commercial use. Lupin stated that the partnership programme is …

Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform